|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A randomized, double-blind, placebo controlled, 3- part,adaptive design, multicenter study to assesssafety, tolerability and efficacy of tropifexor (LJN452) in patients withnon-alcoholic steatohepatitis (NASH) - NASH
A multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis - Multi-part, double blind study to assess safety, tolerability and efficacy of LJN452 in PBC patients
A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR
The purpose of the study was to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH
100 Clinical Results associated with FXR x CCR2 x CCR5
100 Translational Medicine associated with FXR x CCR2 x CCR5
0 Patents (Medical) associated with FXR x CCR2 x CCR5